The Neuro-Oncology Programme is a network of researchers and clinicians in Cambridge working in brain tumour research.
Over 11,000 people are diagnosed with new cases of brain or central nervous system (CNS) cancer every year in the UK, and the outlook for patients has changed little over the past 10 years.
Brain tumours have been defined as a cancer of unmet need.
The Programme is focusing research and networking efforts around 4 key themes:
- Imaging and Tumour Metabolism
- Developmental Neurobiology
- Epi/genomics of recurrence, transformation and treatment resistance
- Brain metastases
At the heart of the Programme is the Neuro-oncology MDT and the newly formed Brain Tissue Bank at Addenbrookes. Data from tissue samples, along with the Neuro-oncology MDT will become the hub of an integrated cancer medicine approach to brain tumour diagnosis and management. Ultimately this approach has the potential to benefit clinical care in the short, medium and longer term.
The Programme also plays an active role in providing projects and training for students in the Centre, supporting the next generation of researchers and building collaborative links between Programme members.
Combining developmental neurobiology, epigenetics, stem cell science and genomic approaches, the Pathania group looks to reveal the role of chromatin remodelling in paediatric high-grade glioma.
Rohit Sinha, who started his Clinical Research Fellowship in 2017 explains his research and why he applied to the CRUK Cambridge Centre for a clinical fellowship.
The Cancer Research UK Children’s Brain Tumour Centre of Excellence (CRUK-CBTCE) brings together teams at the University of Cambridge and the Institute of Cancer Research (ICR) to revolutionise the approach to research and treatment of paediatric brain tumours, drawing on the host institutions' strengths in therapeutic discovery.
To forge an innovative four-stage pipeline that generates curative treatments for children with brain tumours.
To transform the way, the world develops treatments for children with brain tumours.
The research strategy for the CRUK-CBTCE is centred on their biology, drug discovery and development pipeline, which will leverage the expertise of the brightest minds in the paediatric brain tumour field. For more information on the CRUK-CBTCE, please visit their website.
Following Tessa Jowell’s call for action to improve brain tumour treatment, research and survival, the Tessa Jowell Brain Cancer Mission (TJBCM) was formed. The mission consists of passionate academics, doctors, members of cancer charities, patients, and other individuals to help facilitate a new national strategy for brain tumours.
The TJBCM serves as a convening body for these organisations, enabling them to work together to make a tangible change in brain tumour treatment and research. TJBCM is neither a charity, fundraising nor grant-awarding body.
Over the next five years the TJBCM is focusing on six strategic objectives, organised through individual Strategic Programmes. These initiatives are:
- Clinical trials
- Training for physicians
- Emerging data and technology
- Tessa Jowell Centre Designation